The impact of positron emission tomography in the radiotherapy treatment planning

Neoplasma

Volumn 54, Issue 2, 2007, Pages 95-100

  Dolezelova H ^a   Slampa P ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Positron emission tomography; Radiotherapy; Target volume

Indexed keywords

BRAIN TUMOR; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ESOPHAGUS CARCINOMA; HEAD AND NECK CANCER; HUMAN; LUNG CARCINOMA; LYMPHOMA; MEDICAL INFORMATION; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; TREATMENT PLANNING; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; COMPUTER ASSISTED RADIOTHERAPY; NEOPLASM; REVIEW; SCINTISCANNING;

DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 34347245632     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (39)

1. BUJENOVIC S. The role of positron emission tomography in radiation treatment planning. Sem Nucl Med 2004; 34: 293-299. (Pubitemid 39361038)
2. GROSU AL, PIERT M, WEBER WA, JEREMIC B, PICCHIO M et al. Positron emission tomography for radiation treatment planning. Strahlenther Oncol 2005; 8: 483-499. (Pubitemid 41059518)
3. COHADE C, WAHL R. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvement. Sem Nucl Med 2003; 33: 228-237.
4. RIGO P, HUSTINX R, BURY T. PET imaging in lung cancer. In: VALK PE, BAILEY DL, TOWNSEND DW, MAISEY MN, editors. Positron Emission and Tomography: Basic Science and Clinical Practice. London, UK: Springer, 2003; 517-534.
5. VANSTEENKISTE JF, STROOBANTS SG, DELEYN PR. Lymph node staging in non-small cell lung cancer with FDG-PET: A prospective study on 690 lymph node stations from 69 patients. J Clin Oncol 1998; 16: 2142-2149.
6. VANSTEENKISTE JF, STROOBANTS SG, DUPONT PJ. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localization of regional lymph node metastases? Eur J Nucl Med 1998; 25: 1495-1501
7. VAN DER WELL A, NIJSTEN S, HOCHSTENBAG M, LANERS R, BOERSMA L et al. Increased therapeutic ratio by 18FDG-PET-CT planning in patients with clinical CT Stage N2/3 M0 non-small cell lung cancer (NSCLC): A modeling study. Int J Radiat Oncol Biol Phys 2005; 61:649-655.
8. HICKS RJ, KALFF V, MACMANUS MP. (18) F-FDG-PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001; 42: 1596-1604.
9. WEBER WA, DIETLEIN M, HELLWIG D. PET with (18)Fluorodeoxyglucose for staging of non-small cell lung cancer. Nucl Med 2003; 42: 135-144.
10. GOULD MK, KUSCHNER WG, RYDZAK CE, MACLEAN CC, DEMAS AN et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003; 139: 879-892.
11. MAH K, CALDWELL CB, UNG YC, DANJOUX CE, BALOAH JM et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell-lung carcinoma: A prospective study. Int J Radiat Oncol Biol Phys 2002; 52: 339-350.
12. RUYSSCHER D, WANDERS S, VAN HAREN E, HOCHSTENBAG M, GEERAEDTS W et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small cell lung cancer: A prospective clinical study. Int J Radiat Oncol Biol Phys 2005; 62: 988-994.
13. EMAMI B, MIRKOVIC N, SCOTT C, BYHARDT R, GRAHAM MU et al. The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: An analysis of RTOG data. Lung Cancer 2003; 41: 207-214.
14. RUYSSCHER D, WANDERS S, MINKEN A, LUMERS A, CHIFFELERS J et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: A planning study. Radiat Oncol 2005; 77: 5-10.
15. BRADLEY J, THORSTAD WL, MUTIC S, MILLER TR, DEHTASHTI F et al. Impact of FDG-PET detection on radiation therapy volume delineation in NSCLC. Int J Radiat Oncol Biol Phys 2004; 59: 78-86. (Pubitemid 38501510)
16. STUCKENSEN T, KOVACS A, ADAMS S. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 2000; 28: 319-324.
17. STOECKLI S, STEINERT M, PFALTZ M. Is there a role for positron emission tomography with 18-F fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinomas? Head Neck 2002; 24: 345-349.
18. PAULINO AC, KOSHY M, HOWELL R. Comparison of CT and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2005; 61: 1385-1392.
19. KONSKI A, DOSS M, MILESTONE BHALUSZKA O, HANLON A et al. The integration of 18-fluoro-deoxy.glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys 2005; 61: 1123-1128. (Pubitemid 40340906)
20. KATO H, KUWANO H, NAKAJIMA, MMIYAZAKI T, YOSHIKAWA M et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002; 94: 921-928. (Pubitemid 34150845)
21. RICE TW. Clinical staging of esophageal carcinoma. CT, EUS and PET. Chest Surg Clin N Am 2000; 10: 417-485.
22. Swartz DL, Ford E, Rajendran J et al. FDG-PET/CT imaging for preradiotherapy staging of head-and -neck squamous cell carcinoma. Int J Radiat Oncol Biol Phy 2005;61:129-136 (Pubitemid 40039114)
23. FLANAGAN F, DEHDASHTI F, SIEGEL B. Staging of esophageal cancer with 18F-fluorodeoxyglusoce positron emission tomography. Am J Roentgenol 1997; 168: 417-424. (Pubitemid 27051977)
24. NARAYAN K, HICKS RJ, JOBLING T. A comparison of MRI and PET scanning in surgically staged locoregionally advanced cervical cancer. Potential impact on treatment. Int J Gynecol Cancer 2001; 11: 263-271.
25. SINGH AK, GRIGSBY PW, DEHDASHTI F, HERZOG TJ, SIEGEL BA et al. FDG-PET lymph node staging and survival of patients with FIGO Stage IIIb cervical carcinoma. Int J Radiat Oncol. Biol. Phys 2003; 56: 489-493.
26. PERRY W, GRIGSBY PW, BARRY A, SIEGEL BA, DEHDASHTI F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001; 19: 3745-3749. (Pubitemid 32844787)
27. GRIGSBY PW, SIEGEL BA, DEHDASHTI F. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys 2003; 55: 907-913.
28. ROSE PG AL, ADLER LP, RODRIGUEZ M, FAULHABER PF, ABDUL-KARIM FW et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999; 17: 41-45.
29. STRUMPE K, URBINELLI M, STEINERT H. Whole body positron emission tomography using fluorodeoxyglucose for staging lymphoma: Effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721-728.
30. LEE YK, COOK G, FLOWER MA, ROWBOTTON C, SHAHDI M et al. Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiat Oncol 2004; 73: 277-283.
31. CIERNIK IF, DIZENDORF E, BAUMERT BG, REINER B, BURGER C et al. Radiation treatment planning with an integrated positron emission and computed tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003; 57: 853-863.
32. HERHOLZ K, HOLZER T, BAUER B., SCHRODER R, VOGES J et al. 11C-methionine PET for differential diangosis of low grade gliomas. Neurology 1998; 50: 1316-1322.
33. VOGES J, HERHOLZ K, HOLZER T. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg 1997; 69: 129-135. (Pubitemid 28305431)
34. GROSU AL, WEBER WA, FRANZ M, STÄRK S, PIERT M et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 511-519.
35. GROSU AL, WEBER WA, RIEDEL E, JEREMIC B, NIEDER C et al. L-(Methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 64-74.
36. NUUTINEN J, SONNINEN P, LEHIKOINEN P, SUTINENI E, VALAVAARA R et al. Radiotherapy treatment planning and low-term follow-up with [(11)C] methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 2000; 48: 43-52.
37. SCHWAIGER M. Molecular imaging as possible clinical tool. Program and abstracts of ECCO 13: The European Cancer Conference; October 30-November 3, 2005; Paris, France. Abstract 63.
38. GAMBHIR SS, CZERNIN J, SCHWIMMER J, SILVERMAN DHS, COLEMAN RE et al. A tabulated summary of the FDG-PET literature. J Nucl Med 2001; 42: S1-93.
39. HUEBNER R, PARK KC, SHEPARD J. Meta-analysis of the literature for whole body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41: 1177-1189.